While the glutamatergic system is implicated in the pathophysiologies of both schizophrenia and major depression, the use of mGluR5 PAMs for the treatment of schizophrenia and NAMs for the treatment of depression, suggests opposing disturbances of the glutamatergic system in these disorders. This evidence concerns the gene GRM5 and major depressive disorder.